{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for angiotensin root_codes_code in Code Literal (approximate match)
Class:
PROTEIN
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
NCT00084071: Phase 3 Interventional Completed Pneumonia
(2004)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01441115: Phase 1 Interventional Terminated Cancer
(2011)
Source URL:
Class:
PROTEIN
Effector Cell Institute is developing Nagrestipen (ECI 301) for the treatment of cancer. Preclinical studies of ECI 301, a mutant derivative of macrophage inhibitory protein-1α (a single amino-acid substituted MIP-1α), have shown that its administration can improve the antitumor effects of radiotherapy in a manner associated with a tumor-independent abscopal effect. ECI 301 enhanced tumor growth inhibition and the abscopal effect (an effect distal to the target) following local antitumor therapy such as radiation, radiofrequency ablation (RFA), or hyperthermia treatment. Nagrestipen has been used in trials studying the treatment of cancer.
Class:
PROTEIN
Status:
US Previously Marketed
First marketed in 1921
Class:
PROTEIN
Status:
Investigational
Source:
USAN:LOTRAFILCON A [USAN]
Source URL:
Class:
POLYMER
Status:
Investigational
Source:
USAN:HIOXIFILCON B [USAN]
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
M021
(2024)
Source URL:
First approved in 2005
Source:
Numark Multivitamins by NUMARK BRANDS, INC
Source URL:
Class:
STRUCTURALLY DIVERSE
